Objective: To test the safety and efficacy of aerosolized beta-2 adrenergic agonisttherapy (Albuterol Sulfate, USP) for improving clinical outcomes in patients with acutelung injury using a placebo controlled, double blinded randomized design. Hypothesis: Beta-2 adrenergic agonist therapy will improve clinical outcomes inpatients with acute lung injury (ALI). The potential mechanisms for improved outcomesinclude a decrease in pulmonary inflammation, reduction in lung endothelial andepithelial permeability, and enhanced resolution of alveolar edema.